Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

ASTRAZENECA (AZN)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

UK Lawmakers Say Parallel Trade Causing Drug Shortages

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/15/2012 | 02:28pm CEST

-- Parliamentary group says urgent action needed to end UK drug shortages

-- Blames European 'parallel trade' in medicines for drug shortages

-- Lawmakers say situation will worsen without corrective action

-- Says possible prohibition of drug exports needs to be considered

(Adds comment from group's chairman, the pharmaceutical industry, an analyst and background.)

 
    By Sten Stovall 
    Of  
 

The U.K. is being drained of crucial medicines by exporters who sell them on elsewhere at higher prices, putting patients' well-being at risk, U.K. lawmakers said Tuesday.

Parliament's All-Party Pharmacy Group called on the coalition government to find effective ways to restrict this so-called parallel trade, which is legal under European Union law but has long been condemned by drug makers. In the past, drug makers have complained about cheap parallel imports flooding into the country.

"The parallel export of medicines intended for the U.K. market is undermining the effective functioning of the U.K. medicines supply chain, and putting patients' well-being at risk," the APPG said in its report.

It noted that while European law provides for the free movement of goods across borders within the E.U., there is also scope to exempt certain goods if their free movement threatens public health.

"We believe the government needs to consider the use of this exemption in the best interests of U.K. patients," the report said.

Supporters of parallel trade in medicines say that it helps stimulate competition and keep drug prices low across Europe while critics believe it disrupts supplies and prevents patients getting access to drugs at prices they can afford.

Pharmaceutical industry experts say a price gap on some medicines, fuelled by a relatively weak pound in the past and higher prices in parts of Europe compared with subsidized prescription charges in the U.K., is behind a shortage of some drugs. Medicines are exported elsewhere by middlemen such as wholesalers or pharmacies seeking quick, larger profits, meaning supplies can become exhausted quickly.

"The issue has become more acute thanks to the drug price cuts that have been pushed through in several European countries over the past three years, which have resulted in bigger disparities in prices - and therefore potentially higher profits for traders," said Ana Nicholls, healthcare analyst at the Economist Intelligence Unit.

Drug manufacturers have tried restrict the practice by imposing quota limits for some drugs in a bid to stop such exports. But the British lawmakers said such action has made the situation worse in the country by restricting the amount of drugs in the supply chain.

APPG Chairman Kevin Barron called on the government to act.

"Other countries experiencing the same problem are now looking into the possibility of prohibiting the export of medicines, and this government needs to urgently look at what they can learn from this," Barron said. In particular, the U.K. government must study the French government's recent proposal to effectively curtail the export of medicines, he added.

The lawmakers' report criticized the U.K.'s Department of Health and the Medicines and Healthcare products Regulatory Agency for poorly monitoring of the problem.

"The Medicines and Healthcare products Regulatory Agency has pledged to address shortages and to tackle those in the supply chain who are not meeting their obligations. However, beset by a lack of market-wide data the regulator does not even know which products are in shortage, much less by whom they are being exported."

"The Department of Health has also seemed reluctant to take action without having hard evidence that patients have been affected," it added.

A spokesperson for the Department of Health said the situation was difficult to monitor.

"There are nearly 900 million prescriptions dispensed a year, almost 11,000 community pharmacies and some 16,000 medicines, so some shortages and delivery delays are inevitable," the spokesperson said. "We will carefully consider the recommendations the All-Party Pharmacy Group make in their report."

The MHRA declined to comment but the U.K.'s pharmaceutical industry broadly welcomed the report's conclusions.

"We are satisfied that the APPG has acknowledged that diversion of U.K. medicines stock to other countries by a minority of pharmacists and other traders has created significant challenges for companies supplying medicines to U.K. patients, which must be addressed," a spokesperson for AstraZeneca PLC (AZN) said.

But Stephen Whitehead, who heads the Association of the British Pharmaceutical Industry, said the lawmakers' recommendations don't go far enough.

"Without the legal separation of pharmacy wholesaling and dispensing activities, the industry is unable to prioritize pharmacists whose primary concern is U.K. patients, over those who are selling medicines abroad for a profit and causing the problems in the supply chain," he said. "The pharmaceutical industry will continue to work closely with pharmacists, wholesalers, and the Department of Health to help improve this situation."

-By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA
10/20 ASTRAZENECA : lobbies for personalized asthma care with new visual snapshot tool
10/20 ASTRAZENECA : US FDA accepts regulatory submission for Lynparza in metastatic br..
10/19 ASTRAZENECA : Researchers from AstraZeneca Report on Findings in Disease Progres..
10/19 ASTRAZENECA : TAGRISSO® osimertinib Granted Breakthrough Therapy Designation by ..
10/19 ASTRAZENECA : Findings on Antibiotics Reported by Investigators at AstraZeneca (..
10/19 ASTRAZENECA : Reports Outline Obesity, Fitness and Wellness Study Results from A..
10/19 ASTRAZENECA : US FDA accepts supplemental Biologics License Application for IMFI..
10/18 ASTRAZENECA : Announces New Data Showing US Preterm Infants at Significantly Gre..
10/18 ASTRAZENECA : US FDA Accepts Regulatory Submission for LYNPARZA® (olaparib) in M..
10/18 FDA ACCEPTS ASTRAZENECA PLC (ADR)(NY : AZN) Imfinzi’s Supplemental Biologi..
More news
News from SeekingAlpha
10/20 Tracking Ken Fisher's Fisher Asset Management Portfolio - Q3 2017 Update
10/19 3 THINGS IN BIOTECH YOU SHOULD LEARN : October 19, 2017
10/19 YOUR DAILY PHARMA SCOOP : Gilead's Brave New World, AZN's Lynparza SNDA, RXDX En..
10/18 FDA accepts Myriad Genetics' application for companion diagnostic test for As..
10/18 YOUR DAILY PHARMA SCOOP : AZN's Imfinzi SBLA; Ablynx U.S. IPO; Is Teva A Buy?
Financials ($)
Sales 2017 21 558 M
EBIT 2017 5 959 M
Net income 2017 2 524 M
Debt 2017 12 193 M
Yield 2017 4,00%
P/E ratio 2017 30,76
P/E ratio 2018 25,99
EV / Sales 2017 4,55x
EV / Sales 2018 4,50x
Capitalization 85 977 M
Chart ASTRAZENECA
Duration : Period :
AstraZeneca Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Average target price 66,4 $
Spread / Average Target -2,4%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA16.62%85 977
JOHNSON & JOHNSON23.29%382 202
NOVARTIS13.50%226 404
PFIZER11.58%216 886
ROCHE HOLDING LTD.5.55%207 116
MERCK AND COMPANY7.88%174 223